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Summary Introduction
We previously reported that change, with age, in plasma
Apolipoprotein E (apoE) is a component of very-low-levels of total cholesterol (TC) and LDL cholesterol
density lipoprotein (VLDL) and HDL particles and is a(LDL-C) differed between apolipoprotein E (APOE) ge-
ligand for lipoprotein receptors. The apoE-gene locusnotypes e3e3 and e3e4, in a sample of 77 older, unre-
on chromosome 19 (APOE) has three common alleles—lated males. By use of a larger sample from that cohort,
e2, e3, and e4—with relative frequencies .08, .77, andfollowed longitudinally during 1969–87, the change in
.15, respectively; the protein products of these allelesTC and in LDL-C, between the e3e3 and e3e4 APOE
differ by a single amino acid (Zannis et al. 1981; Cum-genotypes, over three exams, was reanalyzed. Addition-
ming and Robertson 1982; Sing and Davignon 1985).ally, the change in triglycerides (TG) and in HDL-choles-
The apoE polymorphism has been estimated to be re-terol (HDL-C), between the e3e3 and e3e4 APOE geno-
sponsible for 4%–8% of the variation in age- and sex-types—as well as the differences between the e3e3 and
adjusted total cholesterol (TC) and LDL cholesterole3e2 genotypes, for TC, LDL-C, TG, and HDL-C—
(LDL-C) levels in the general Caucasian populationwere contrasted over the three exams. At exam 1 TG
(Sing and Davignon 1985; Boerwinkle and Sing 1987)was higher in the e3e4 group than in the e3e3 group
and may contribute to risk of coronary artery disease(mean age 48 years), and at exams 2 and exam 3 (mean
(CAD; see reviews by Davignon et al. 1988; Mahleyages 58 and 63 years, respectively) it was similar (P
1988). The e4 allele has been reported to have an aver- .009 for the exam-by-genotype–interaction effect in
age effect of increasing TC by 5–8 mg/dl and increasingthe repeated-measures analysis). A similar trend was
LDL-C by 7 mg/dl. The e2 allele has been reported toseen for TC (P  .03), yet previously detected LDL-C
have an average effect of decreasing TC and LDL-C byeffects were not apparent (P  .46). Those with the
11-14 mg/dl (Sing and Davignon 1985). Meta-analysise3e2 genotype had higher TG and lower LDL-C and
suggests that, relative to the e3 allele, both the e2 alleleTC at each exam than were seen in those with the e3e3
and the e4 allele may be associated with increases ingenotype, although the differences in the values were
plasma triglyceride (TG) levels (Dallongeville et al.not always statistically significant. Differences in TC,
1992). The e4 allele was found to be associated withLDL-C, and TG, between the e3e2-genotype and e3e3-
earlier age of myocardial infarction (MI), in studies ofgenotype groups, did not significantly change over the
MI survivors (Cumming and Robertson 1984; Lenzenthree exams. HDL-C levels were relatively stable over
et al. 1986) with angiographic evidence of CAD (Kuusithe exams; however, the exam-by-genotype interaction
et al. 1989) and with clinical ischemic disease (Wilsonwas significant for the e3e2 genotype versus the e3e3
et al. 1994). APOE-genotype distribution has beengenotype (P  .02). The e4 allele effects on TG and TC
found to differ between MI survivors and controlschanged between longitudinal exams and may be age
(Cumming and Robertson 1984). However, other stud-dependent. Changes, with age, in the effect of the e3e4
ies have failed to find an association with presence orgenotype on lipids may impact the risk of developing
severity of CAD (Menzel et al. 1983; Reardon et al.atherosclerotic disease.
1985). ApoE molecules derived from the three alleles
vary in their in vitro receptor-binding ability (Mahley
1983), in their catabolic rates (Gregg et al. 1986; De-Received August 22, 1996; accepted for publication April 27, 1997.
Address for correspondence and reprints: Dr. Gail P. Jarvik, Divi- mant et al. 1991), and in the plasma concentration of
sion of Medical Genetics, University of Washington Medical Center, apoE protein present in vivo (Utermann 1985). The
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Table 1phism effects on TC and LDL-C in octogenarians. At
the same time, they found a decrease in the frequency
Mean Age and Lipid Levels in the Entire NHLBI Twin Sample and
of the e4 allele in octogenarians, which has been docu- in Those with APOE Genotypes Who are Considered in This Study
mented in other aging populations (Cauley et al. 1993;
All Those withSchachter et al. 1994; Jarvik et al. 1995). They suggested
All NHLBI Twins APOE Genotypesthat differential survival, based on lipid differences, ac-
counted for both the loss of e4 alleles and the equaliza-
Exam 1:
tion of TC and LDL-C. An alternative hypothesis—that Age (years) 47.9 (n  1,028) 47.8 (n  590)
the equalization of lipids was an aging effect and that TC (mg/dl) 220.3 (n  1,023) 221.0 (n  587)
LDL-C (mg/dl) 143.6 (n  1,010) 145.7 (n  560)the loss of e4 alleles in the older samples was likely due
TG (mg/dl) 133.1 (n  1,017) 132.4 (n  585)to the subsequently found association of the e4 allele
HDL-C (mg/dl) 45.3 (n  1,013) 46.03 (n  560)with Alzheimer disease (Corder et al. 1993; Yu et al.
Exam 2:
1994; Jarvik et al. 1995)—was supported by evidence Age (years) 57.6 (n  784) 57.7 (n  548)
of a longitudinal decline in the TC and LDL-C of men TC (mg/dl) 211.6 (n  785) 213.3 (n  548)
LDL-C (mg/dl) 135.1 (n  764) 136.6 (n  529)with the e3e4 genotype at age 48–63 years, compared
TG (mg/dl) 161.2 (n  785) 161.8 (n  548)with no difference in TC and LDL-C by the age of 48–
HDL-C (mg/dl) 45.6 (n  784) 46.2 (n  547)63 years in men with the e3e3 genotype without evi-
Exam 3:
dence of loss of e4 alleles (Jarvik et al. 1994). Although Age (years) 63.2 (n  622) 63.2 (n  590)
a statistically significant result was found, the sample TC (mg/dl) 220.2 (n  584) 220.6 (n  560)
LDL-C (mg/dl) 148.2 (n  550) 148.2 (n  528)size—77 unrelated individuals—was small. The goal of
TG (mg/dl) 147.3 (n  584) 148.3 (n  560)the present study is to reevaluate the results of Jarvik et
HDL-C (mg/dl) 45.6 (n  584) 45.8 (n  560)al. in a larger sample drawn from the same population
and to extend it to examine both the longitudinal effect
of the e2 allele and the effects of all alleles on longitudi-
nal change in TG and HDL cholesterol (HDL-C). shown to be typical of the age-specific population lipid
distributions (Jarvik et al. 1994). Because of small sam-
ple sizes, the e4e4, e2e2, and e2e4 genotypes were notSubjects and Methods
included in the contrasts. Additionally, 43 individuals
Subjects who either were under treatment for non–insulin-de-
pendent diabetes or were treated with lipid-loweringThe study subjects were participants in the National
Heart, Lung, and Blood Institute (NHLBI) Twin Study medications at any of the three examinations were ex-
cluded, leaving 436 individuals available for analysis.(Feinleib et al. 1977; Selby et al. 1991), composed of
Caucasian male twin pairs born during 1917–27, all of Analyses considered genotyped individuals who at-
tended and had TC measured at all three exams. Unre-whom had served in the U.S. military. Of 560 DZ pairs
originally solicited, 260 participated in clinical examina- lated subsamples drawn from the twins assured the inde-
pendence of observations, which is an assumption oftions during 1969–73, and 183 pairs returned for a
second examination during 1980–81. A third examina- the statistical tests. To allow maximum sample sizes,
separate subsamples were drawn for the e2e3-versus-tion of 129 of the original 260 pairs was conducted
during 1986–87. Of the 260 DZ pairs initially exam- e3e3 analysis and for the e3e4-versus-e3e3 analysis (Jar-
vik et al. 1994). In each case, all singletons with a geno-ined, 58 individuals in 55 pairs died between the first
and third examinations (Reed et al. 1991, 1993). Of the type of interest were included in the unrelated sample.
One twin from each MZ pair was randomly chosen.505 MZ pairs solicited, 254 pairs participated in the
first exam, 179 pairs returned for the second exam, and For the DZ pairs, siblings with the rarer e2e3 and e3e4
genotypes, rather than their e3e3 siblings, were preferen-138 pairs returned for the third exam. Of the original
253 MZ pairs, 38 individuals from 36 pairs died prior tially included in the unrelated sample, to increase the
sample size of those genotypes. The first subsample con-to the third exam (Selby et al. 1991). Thus, 96 (9.3%)
of the original 1,026 subjects died before the third exam. structed included 71 e3e4 individuals and 177 e3e3 indi-
viduals; the second included 32 e2e3 individuals andAPOE genotypes were determined for all individuals
with available samples from the third exam. Genotypes 183 e3e3 individuals. For both subsamples, mean ages
were 48 years at exam 1, 58 years at exam 2, and 63were available for 590 men: 122 DZ pairs, 124 MZ
pairs, and 41 DZ and 57 MZ singletons whose twins years at exam 3. At the third exam, the age range was
59–70 years.were not available. The subset of the NHLBI twin sam-
ple on which genotypes were available had age and lipid We previously reported (Jarvik et al. 1994) the differ-
ences in the TC and LDL-C changes, with age, betweendistributions typical of the total group (table 1). These
distributions in the total NHLBI sample have been e3e3 and e3e4 genotypes of 77 men from the larger
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sample selected, without knowledge of lipid levels or of analysis was repeated after deletion of the samples from
Framingham, which had significantly different means atCAD status, from third-exam participants. The current
analyses for the e3e4 and e3e3 unrelated individuals are exam 1.
The differences in TC, LDL-C, TG, or HDL-C, be-reported for subsamples both with and without both
those individuals who were considered in the original tween exam 3 and exam 1, were also contrasted between
the e3e3 and e3e4 genotypes and between the e3e3 andreport and their twin brothers, to evaluate the compara-
bility of the current results and the original results. the e2e3 genotypes, by use of two-sample t-tests. Within
exams, one-way ANOVA was used to test whether geno-
Methods type groups differed in their mean differences of TC,
LDL-C, TG, or HDL-C, within exams 1, 2, and 3. Be-Laboratory methods.—TC and TG were measured en-
zymatically (Allain et al. 1974). HDL-C was estimated cause of statistically significant skewness in the distribu-
tion of TG and HDL-C at one or more exams, TG andby the method of Warnick et al. ( 1982). LDL-C was
estimated (Friedewald et al. 1972) only if the measured HDL-C were ln transformed (ln-TG) for all statistical
tests, except for the test of exam 3 minus exam 1 differ-TG (Sampson et al. 1975) level was 400 mg/dl (War-
nick et al. 1990). At exam 1 the analyses were done in ences. Outliers with TG 500 mg/dl were excluded
from statistical tests involving TG: this resulted in thethree labs (Framingham, Indianapolis, and San Fran-
cisco [Christian et al. 1976]). The labs exchanged speci- exclusion of two e3e3-genotype men from the repeated-
measures sample. Although multiple comparisons weremens, to maintain standardization. There was no differ-
ence in mean, by lab, for TC, LDL-C, or TG. The made in this study, the major goal was to look for exam-
by-genotype interaction, and the variables and testFramingham lab did have a lower mean for HDL-C (4–
5 mg/dl [Christian et al. 1976]). At exam 2 the West hypotheses are highly correlated. For this reason, no
adjustments for multiple comparisons were made. AllCoast lab was at Stanford (Christian et al. 1987). All
labs again used the standardized methods. All lipid tests above-described statistical analyses used the SPSS (1991)
statistical package.at exam 3 were done at Stanford (Christian et al. 1990).
APOE genotyping was performed by use of digestion of The proportion of variance due to variation in APOE
genotype was computed as the variance associated withPCR amplification products with HhaI, as described by
Hixson and Vernier (1990). APOE genotype, VE, divided by the total variance, VT,
where VE  Sjfj(mP . . 0 mP j)2 when j  1, . . . , 6 APOEStatistical analyses.—Preliminary analyses included
computation of the relative allele frequencies, by allele genotypes and when fj represents the frequency of the
jth genotype. Sib-pair linkage methods, using Sibpalcounting and x2 goodness-of-fit testing, to determine
whether the numbers of individuals with each of the six 2.6a (Tran et al. 1994), were attempted for the following
traits: TC, LDL-C, ln-TG, and ln-HDL-C at each exampossible genotypes were in proportions consistent with
Hardy-Weinberg population expectations. Unrelated in- and their change between exams 1 and 3. However, a
maximum of only 115 DZ pairs for whom both sibsdividuals were selected for statistical analyses, in order
to avoid violation of statistical tests. Statistical tests that were not excluded were available, and power was insuf-
ficient to detect evidence of linkage for any trait.include related individuals should be interpreted with
caution.
In the unrelated subsets, repeated-measures analysis Results
of variance (ANOVA) was used to test the hypothesis
Preliminary Analysesthat the change in TC, LDL-C, TG, or HDL-C levels at
exams 1, 2, and 3 (categorical measures) differed be- The APOE-genotype distribution in the 590 men was
as follows: 11 (1.9%) e2e2, 50 (8.5%) e2e3, 22 (3.7%)tween the e3e3 and the e3e4 genotypes and between the
e3e3 and the e2e3 genotypes. The repeated-measures e2e4, 374 (63.3%) e3e3, 121 (20.5%) e3e4, and 2
(2.0%) e4e4 individuals. For the unrelated group of 344test used the SPSS MANOVA command (SPSS 1991;
Sheeber et al. 1996). No assumptions were made with men (with no exclusions), the relative allele frequencies
were as follows: .075 for e2, .779 for e3, and .145 forregard to a straight-line pattern over exams. Repeated-
measures analysis included a genotype effect and an e4. These relative allele frequencies were similar to those
seen in other, nonelderly Caucasian populations (Singexam effect, in addition to the testing for an exam-by-
genotype–interaction effect, in the prediction of TC, and Davignon 1985). The genotype distribution was not
significantly different from Hardy-Weinberg equilib-LDL-C, TG, or HDL-C levels. All repeated-measures
analyses were repeated on TC, LDL-C, ln-TG, and ln- rium proportions (P  .43). Both results suggest that
significant selection against a genotype is not present inHDL-C, adjusted for age at intake, by use of the residu-
als resulting from linear regression. Similarly, those anal- this sample. The lipid levels for all individuals present
at all three exams who who were not taking lipid-low-yses were repeated after adjustment for body-mass index
(BMI). Additionally, the HDL-C repeated-measures ering or antiglycemic oral medications are shown in ta-
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ble 2. The proportion of the variance, in TC, LDL-C, exam 2; and r  0.06 for e3e3 and r  .15 for e3e4
and TG, associated with the APOE genotype was esti- for exam 3). The TC–TG correlations did not differ
mated by use of randomly drawn unrelated individuals significantly at any exam (r  .40, .34, and .25 for e3e3
from each exam who were not taking lipid-lowering at exams 1, 2, and 3, respectively; and r  .27, .30, and
or antiglycemic oral medications. The range of these .03 for e3e4 at exams 1, 2, and 3, respectively). No
estimates was 1.7%–7.4%; they are shown in table 3. correlation differences between e3e3 and e2e3 genotypes
The TC and LDL-C estimates are somewhat lower than were detected at any exam. Power may be limited for
those in younger, mixed-gender samples available from some of these contrasts. Change in TC, LDL-C, ln-TG,
the literature, which are also shown and referenced in or ln-HDL-C between exams 1 and 3 was significantly
table 3, although no other male-only samples were iden- different between the e3e3 and e3e4 genotypes only for
tified. The estimates for variance associated with TG ln-TG (P  .005) and TC (P  .023); between exams 1
are higher than those previously reported for younger, and 3, there was no significant difference between the
mixed-gender samples, even when the total TG variance e2e3 and e3e3 genotypes, for change in TC, LDL-C,
is not previously adjusted for age and BMI. However, ln-TG, or ln-HDL-C.
Haviland et al. (1995) have reported, in octogenarian
males, a higher proportion of variance due to APOE Repeated Measures
genotype. The proportion of the variance in unadjusted
Unrelated individuals, enriched for either the e2e3 orHDL-C levels that is attributable to APOE genotype was
the e3e4 genotype, as described in the Methods subsec-estimated to be 1.1%, 1.8%, and 0.9%, respectively,
tion, were used for the repeated-measures analysis; theirfor exams 1, 2, and 3. Estimates for the proportion of
mean lipid levels are plotted in figure 1. Repeated-mea-variance due to APOE genotype do not differ markedly
sures ANOVA found significant interaction betweenin all those for whom data were available at each exam,
exam and e3e3 versus e3e4 genotype in the predictionversus those who came to all three exams. This further
of TC (P  .034) and ln-TG (P  .009) but not insuggests that the individuals who came to all three ex-
prediction of LDL-C (P  .47) or ln-HDL-C (P  .91)ams and who therefore were useful for the longitudinal
(table 4). Interaction of TC and ln-TG, between the e3e3analysis are representative of the larger group.
and e3e4 genotype, indicates that the differences wereANOVA to test for differences in TC, LDL-C, ln-TG,
not consistent over exams; this appears to be due to aand HDL-C between genotypes within each exam was
difference at exam 1, which is not seen at the later ex-performed on the unrelated subsets adjusted for age at
ams. Exclusion of previously studied men and theirentry. The group means are shown in table 4. At each
brothers resulted in a nonsignificant result for exam-by-exam, differences between e3e3 and e3e4 genotypes
genotype interaction in TC prediction (P  .75), al-were not statistically significant, although the results
though the interaction term for ln-TG remained highlywere marginally significant for ln-TG (P .059) at exam
significant (P  .008). There is no apparent reason for1 only. Inclusion of related individuals would result in
differences between the 77 men previously reported andstatistical significance (P  .002). Differences between
their brothers versus the men from pairs that were notthe e2e3 genotype and the e3e3 genotype were present
previously reported, nor were there statistically signifi-in only TC at exam 2 (P  .021) and LDL-C at exam
cant differences between those from pairs that were or3 (P  .031), although the results were marginally sig-
were not previously studied in any test considered herenificant for TC at exam 3 (P  .079), for LDL-C (P
(data not shown). .09) at exams 1 and 2 (P  .08), and for ln-HDL-C
For the e2e3 genotype and the e3e3 genotype, re-at exam 2 (P  .065). A Fisher Z-test was used to deter-
peated-measures ANOVA found no significant exam-mine whether there were statistically significant differ-
by-genotype interaction in the prediction of TC (Pences in the TC-TG, TC–LDL-C, and LDL-C–TG Pear-
 .52), LDL-C (P  .72), or ln-TG (P  .48). No inter-son correlation coefficients between genotypes,
action between e2e3 and e3e3 genotypes indicates thatconsidering those unrelated individuals used in the re-
the differences in mean levels between these groupspeated-measures analyses. Only the LDL-C–TG correla-
were consistent over exams. However, significanttion difference between the e3e3 (r  .28) and e3e4 (r
exam-by-genotype interaction for the e2e3-to-e3e3 0.02) genotypes and the LDL-C–HDL-C correlation
contrast was significant for ln-HDL-C (P  .019), ap-difference between the e3e3 (r  .09) and e3e4 (r
parently because of differences at exam 2 (fig. 2). When 0.20) genotypes, at exam 1, were statistically signifi-
the exam 1 samples from the Framingham lab werecant at the .05 level. The LDL-C–TG correlation was
removed, 26 e2e3-genotype and 141 e3e3-genotype in-not significantly different at exam 2 (r  .17 for e3e3
dividuals remained, and the P value dropped to .057,and r  .07 for e3e4) or at exam 3 (r  .13 for e3e3
without a change in the trend of the exam means. Ad-and r  .021 for e3e4). Nor was the LDL-C–HDL-C
correlation (r  0.07 for e3e3 and r  .04 for e3e4 at justment of TC, LDL-C, ln-TG, and ln-HDL-C for in-
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Table 3
Proportion of Variance, in Lipid levels, Associated with Variation in APOE Genotype
VARIANCE
(%)
MEAN AGE [RANGE]
SOURCE SAMPLE (years) TC LDL-C TG
Sing and Davignon (1985)a Ottawa (n  102; 55 male) 36 [20–59] 6.9 8.3 .9
Boerwinkle et al. (1987)b French (n  223; 109 male) 40 [25–67] 8.7 . . . .0
Boerwinkle and Utermann (1988)c German (n  563; 419 male) 27 [18–59] 4 . . . . . .
Haviland et al. (1995)d 118 Males 86 [80–100] 10.5 [8.4] 11.7 [8.7] 12.1 [8.6]
Present studye Exam 1 (n  330, 317, 328) 48 [44–52] 2.6 (4.2) 7.4 (8.1) 2.8 (2.6)
Present studye Exam 2 (n  304, 299, 296) 58 [54–62] 3.3 (3.2) 3.6 (3.8) 4.7 (5.7)
Present studye Exam 3 (n  312, 296, 312) 63 [59–70] 1.7 (2.0) 4.7 (5.7) 3.6 (3.6)
a Data are adjusted for variance due to age, sex, height, and weight.
b Data are adjusted for variance due to age, sex, height, weight, and hormone usage.
c Data are adjusted for variance due to age and sex.
d Estimates are adjusted for variance due to varying concomitants (in square brackets are estimates without prior adjustments for concomitants).
TC and LDL-C were adjusted for uric-acid levels; and TG was adjusted for height, weight, glucose level, and uric-acid levels.
e Data are for a randomly chosen unrelated group of men with genotypes available from exam 3 who are not taking lipid-lowering or oral
hypoglycemic medications. No outliers are excluded. LDL-C is only measured when TG are 400 mg/dl. For this study, n  x, y, z are the
sample sizes with TC, LDL-C, and TG measured, respectively. The TC, LDL-C, and TG data in parentheses are for the 284 people who had
cholesterol measured at all three exams. The variance estimates from this study are not adjusted for variance associated with age and BMI
within each exam. That variance is 2% for TC and LDL-C at all exams but varies by 12%–15% for TG at each exam. Variance estimates
from other studies may be computed by methods different from that used for this study.
take age or BMI did not change the conclusions of any viously recognized and the APOE effect on TC and LDL-
C may be less important.of the repeated-measures analyses.
An exam-by-genotype interaction is also suggested
when e3e3 and e3e4 genotypes for TC are considered.Discussion
For both TC and LDL-C the differences between geno-
This has study resulted in several new findings. There types are small at exam 1, smaller than those reported
is, from this longitudinal study, evidence of an exam- elsewhere (Jarvik et al. 1994) and those described in
by-genotype interaction in the prediction of TG; that is, younger samples (Sing and Davignon 1985). Some differ-
the pattern of change in TG, over exams, as the men ences between APOE-genotype means for TC and LDL-
became older differed between e3e3 and e3e4 genotypes, C may have already diminished by exam 1 (mean age
after adjustment for age at entry. For TC, LDL-C, and 48 years) in the population described here. This is also
TG, no exam-by-genotype interactions were detectable suggested by the lower estimates of variance due to APOE
for e3e3 versus e3e2. Such an interaction was detected genotype that were seen in this sample versus samples
for HDL-C, although it is a marginal result if, because reported elsewhere (table 3), although it is possible that
of the problem with standardization, the samples done males have less variance due to APOE genotype than
at the Framingham lab at exam 1 are dropped from the do females, although the opposite result was reported in
analysis. The proportion of variance in TC and LDL-C healthy octogenarians (Haviland et al. 1995). Addition-
that was due to variance in APOE genotype was lower— ally, a difference in TC–TG correlations, between geno-
and that of TG was higher (table 3)—in this older, male types, which has been reported for younger populations
sample than that elsewhere reported in younger samples (Boerwinkle et al. 1987), was not detectable at any exam
of mixed gender (Sing and Davignon 1985; Boerwinkle in this sample. The exam-by-genotype interaction for TC
et al. 1987; and Boerwinkle and Utermann 1988). The may reflect the cholesterol contained in VLDL-C, which
TC, LDL-C, and TG variance associated with APOE is highly correlated with TG, since the LDL-C fraction
genotype was higher in a sample of healthy octogenarian of TC had no evidence of an interaction. The contrast
males (Haviland et al. 1995). After adjustment for age between the prior result of a significant interaction term
and BMI, the variance associated with APOE genotype for LDL-C and the current result of no evidence of inter-
is 2% for TC and LDL-C, at all exams, but is 12%– action is not explained by differences in the samples. The
15% for TG at each exam (table 3, footnote). This sug- prior result could represent a type I error—false rejection
gests that in some populations (in this case, older males) of the null hypothesis of no interaction. Further longitudi-
nal studies are warranted.the APOE effect on TG is more important than pre-
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Figure 1 TC, LDL-C, and TG levels, by APOE genotype, in unrelated subjects, at exams 1, 2, and 3; mean ages were 48, 58, and 63
years, respectively. An APOE e3e3 group is contrasted with the e3e4 group (A) and with the e2e3 group (B).
There are at least three possible explanations for the order to be genotyped; however, their lipid levels at each
differences in changes in lipid levels, over time, between age were typical of those seen in the general population
e3e3 and e3e4 APOE genotypes: (1) ascertainment bias, (Jarvik et al. 1994), and their APOE genotypes also were
(2) genotype-specific response to a general change in the representative of populations described elsewhere (Sing
environment over time, or (3) true aging effects, in which and Davignon 1985). The results cannot be due to differ-
the change in lipids with increasing age varies with geno- ential survival within the sample, since the analysis con-
type. Ascertainment bias is unlikely, since these men siders only men present at all exams. APOE genotype–
were selected on the basis of twin status, which is not dependent change in lipids in response to dietary and
expected to correlate with lipid levels. The men did have weight changes have been described in some populations
to be present at the third exam (mean age 63 years) in (Gueguen et al. 1989; Lehtimaki et al. 1992; Uusitupa
et al. 1992; Jenkins et al. 1993; Lopez Miranda et al.
1994). If subjects significantly changed their diet over
the course of the study, their responses could be geno-
type dependent. However, it is unlikely that the TG
decline in the e3e4 group was due to a reduction in
dietary fat or cholesterol, since LDL-C did not decline.
Additionally, adjustment of the lipid levels for BMI at
each exam did not change the results. A true aging effect
is the most likely explanation for this result. Lipid levels
increase with age until the 7th decade and then decline
in males (National and Health 1980; Hershcopf et al.
1982; Alvarez et al. 1984; Newschaffer et al. 1992).
This decline in lipid levels in longitudinal studies of
males after the age of 60 years has been shown to be
due in part to an aging effect that is not due to changes
in weight, diet, or exercise (Hershcopf et al. 1982). It is
possible that the mechanism responsible for these aging
effects in lipids is sensitive to the differences in the APOE
e3 product versus the e4-gene product.
The lack of an exam–by–e3e3-versus-e2e3-genotype
interaction in the prediction of TC levels in this longitu-
Figure 2 HDL-C levels, by APOE genotype, in unrelated sub- dinal study contrasts with a cross-sectional study (Reillyjects, at exams 1, 2, and 3; mean ages were 48, 58, and 63 years,
et al. 1992) that suggested that the regression of TC onrespectively. The APOE e3e3a group is contrasted with the e2e3 group,
and the e3e3b group is contrasted with the e3e4 group. age differs between e2e3-genotype and e3e3-genotype
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Alvarez C, Orejas A, Gonzalez S, Diaz R, Colomo LF (1984)males of age 26–63 years (mean 44 years); however,
Reference intervals for serum lipids, lipoproteins, apopro-differences in either the age distributions of the samples
teins in the elderly. Clin Chem 30:404–406or the designs of the studies may account for the discor-
Boerwinkle E, Sing CF (1987) The use of measured genotypedant results. In a cross-sectional study, APOE-genotype
information in the analysis of quantitative phenotypes in man.effects on plasma apoE concentration were found to
III. Simultaneous estimation of the frequencies and effects ofdiffer with age in both males and females, with the vari-
the apolipoprotein E polymorphism and residual polygenetic
ance due to APOE genotype decreasing in the older ages effects on cholesterol, betalipoprotein and triglyceride levels.
(Zerba et al. 1996), suggesting that the APOE-genotype Ann Hum Genet 51:211–226
effects on plasma level of apoE protein diminishes Boerwinkle E, Utermann G (1988) Simultaneous effects of the
with age. apolipoprotein E polymorphism on apolipoprotein E, apoli-
Fifty-five to 60% of the population is expected to poprotein B, and cholesterol metabolism. Am J Hum Genet
have the e3e3 genotype, 23%–25% the e3e4 genotype, 42:104–112
12%–14% the e2e3 genotype, 2%–3% the e4e4 geno- Cauley JA, Eichner JE, Kamboh MI, Ferrell RE, Kuller LH
(1993) Apo E allele frequencies in younger (age 42–50) vstype, 2% the e2e4 genotype, and 1% the e2e2 geno-
older (age 65–90) women. Genet Epidemiol 10:27–34type. Thus, genetic variation at this locus is quite com-
Christian JC, Borhani NO, Castelli WP, Fabsitz R, Norton JAmon and is expected to contribute significantly to
Jr, Reed T, Rosenman R, et al (1987) Plasma cholesterolpopulation variation in lipid levels. Changes in the
variation in the National Heart, Lung and Blood InstituteAPOE-genotype effects with age may result in difficulties
twin study. Genet Epidemiol 4:433–446both in comparing studies in different age groups and
Christian JC, Carmelli D, Castelli WP, Fabsitz R, Grim CE,in interpreting studies in which age is not carefully con-
Meaney FJ, Norton JA Jr, et al (1990) High density lipopro-
sidered. It is possible that such confounding effects may tein cholesterol: a 16-year longitudinal study in aging male
in part be responsible for the conflicting results found twins. Arteriosclerosis 10:1020–1025
by various studies examining the effects of (a) APOE Christian JC, Feinleib M, Hulley SB, Castelli WP, Fabsitz RR,
genotype on prediction of CAD (Menzel et al. 1983; Garrison RJ, Borhani NO, et al (1976) Genetics of plasma
Cumming and Robertson 1984); reviewed by (Davignon cholesterol and triglycerides: a study of adult male twins.
et al. 1988) and (b) the magnitude of APOE-genotype Acta Genet Med Gemellol 25:145–149
effects on lipids and lipoproteins (Sing and Davignon Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE,
1985; Davignon et al. 1987). This study addresses only Gaskell PC, Small GW, Roses AD, et al (1993) Gene dose
of apolipoprotein E type 4 allele and the risk of Alzheimer’sthe 15-year window of mean age 48–63 years. For LDL-
disease in late onset families. Science 261:921–923C and TC, the data suggest that equalization of genotype
Cumming AM, Robertson FW (1982) Genetics of the apolipo-means between e3e3-genotype and e3e4-genotype males
protein-E isoprotein system in man. J Med Genet 19:417–may begin to occur at age 48 years. Given the docu-
423mented decline in the frequency of the e4 allele with
(1984) Polymorphism at the apoprotein-E locus in rela-age, in addition to the changes in genotype effects with
tion to risk of coronary disease. Clin Genet 25:310–313age that have been described here, possible age interac-
Dallongeville J, Lussier Cacan S, Davignon J (1992) Modula-tions should be carefully considered in studies of APOE-
tion of plasma triglyceride levels by apoE phenotype: a meta-genotype effects on determinants of health in aging pop-
analysis. J Lipid Res 33:447–454
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